Education
About Us
Working with TipRanks
Follow Us
Natalie McClure Insider Profile
4 Followers
Natalie McClure, SVP, Product Development at Adamas Pharmaceuticals, holds 840.00 shares in Adamas Pharmaceuticals (Ticker: ADMS).
Natalie McClure Adamas Pharmaceuticals (ADMS)SVP, Product Development
Adamas Pharmaceuticals (ADMS)
SVP, Product Development
Not Ranked
Natalie McClure has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Natalie McClure does not currently own shares as a corporate insider.
A breakdown of Natalie McClure's holdings
Insider Roles
Natalie McClure does not currently hold a role as a corporate insider.
Roles that Natalie McClure holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Natalie McClure
Natalie McClure's Trading History
List of latest transactions for each holding click on a transaction to see Natalie McClure's performance on stock
You May Also Like
Natalie McClure insider profile FAQ
What is the percentage of profitable transactions made by Natalie McClure?
The percentage of profitable transactions made by Natalie McClure is ―.
What is the average return per transaction made by Natalie McClure?
The average return per transaction made by Natalie McClure is ―.
What stocks does Natalie McClure hold?
Natalie McClure holds: ADMS stocks.
What was Natalie McClure’s latest transaction?
Natalie McClure latest transaction was an Uninformative Buy of $102.45K.
What was Natalie McClure's most profitable transaction?
Natalie McClure’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Natalie McClure's role in Adamas Pharmaceuticals?
Natalie McClure's role in Adamas Pharmaceuticals is SVP, Product Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.